Metagard CR 35mg Tablet contains trimetazidine 35 mg in a controlled-release formulation and is used as add-on treatment for adults with stable angina when first-line antianginal medicines do not adequately control symptoms or are not tolerated. Product records identify Metagard CR 35 mg as a trimetazidine modified-release tablet.

Angina occurs when the heart muscle does not receive enough oxygen-rich blood for its needs. This can cause pressure, tightness, heaviness, or pain in the chest, sometimes with discomfort extending toward the arm, shoulder, neck, jaw, or back. Trimetazidine works differently from medicines that primarily change heart rate or blood pressure. It helps cardiac cells use energy more efficiently during periods of reduced oxygen availability. This metabolic action can support the heart’s energy production and help control symptoms of stable angina.

What is Metagard CR 35mg Tablet used for?

Doctors may prescribe Metagard CR 35mg Tablet as part of a broader treatment plan for stable angina. Current product information describes trimetazidine 35 mg modified-release therapy as add-on treatment for adults whose stable-angina symptoms remain inadequately controlled with first-line antianginal treatment or who cannot tolerate those medicines.

This medicine should not be considered a cure for coronary artery disease. It also does not replace emergency treatment for sudden or severe chest pain. Trimetazidine is not intended to treat an acute angina attack, unstable angina, or a heart attack. Patients experiencing new, severe, persistent, or rapidly worsening chest pain should seek emergency medical attention rather than waiting for this medicine to work.

How does Metagard CR 35mg Tablet work?

The active ingredient, trimetazidine, modifies cardiac energy metabolism by reducing reliance on fatty-acid oxidation and favoring glucose oxidation. This can improve the efficiency of ATP production under conditions of limited oxygen supply. By supporting cellular energy metabolism, trimetazidine can help heart muscle cells function more efficiently during ischemic conditions.

The modified-release formulation gradually releases the medicine. Patients should follow the prescribed schedule and swallow the tablet whole. Do not crush or chew a controlled-release tablet unless a healthcare professional specifically tells you that it is safe to do so.

How should you take it?

Take Metagard CR 35mg Tablet exactly as your prescriber directs. Official product information for 35-mg modified-release trimetazidine commonly describes administration with meals, with dosing adjusted when kidney function is reduced. For moderate renal impairment, a lower frequency may be appropriate, while severe renal impairment is a contraindication. Your physician should determine the correct regimen based on your kidney function, age, medical history, and other medicines.

Take the tablet with water and try to take it consistently at the prescribed times. If you forget a dose, follow your healthcare professional’s instructions rather than taking extra tablets to compensate.

Related Product

Possible side effects

Like other medicines, Metagard CR 35mg Tablet can cause unwanted effects. Reported effects of trimetazidine include dizziness, headache, nausea, vomiting, abdominal discomfort, indigestion, diarrhea, weakness, and skin reactions such as rash or itching.

More importantly, trimetazidine can rarely cause or worsen movement-related symptoms. Tremor, stiffness, difficulty walking, slowed movement, or other Parkinson-like symptoms require prompt medical assessment. Patients with Parkinson’s disease, parkinsonian symptoms, restless-leg syndrome, tremors, or other related movement disorders should generally avoid trimetazidine unless a specialist specifically determines otherwise.

Dizziness can also affect driving or operating machinery. Avoid these activities if the medicine makes you dizzy, sleepy, or less alert.

Important precautions

Before starting Metagard CR 35mg Tablet, tell your doctor about kidney disease, movement disorders, Parkinson’s disease, pregnancy, breastfeeding, or any history of medication allergies. Severe renal impairment is a contraindication, and dose adjustment may be necessary with moderate renal impairment. Older adults may also require additional caution because kidney function can decline with age.

Trimetazidine is not recommended for children under 18 because its safety and effectiveness have not been established in this population. Pregnancy and breastfeeding require medical advice because adequate safety information is limited.

Tell your healthcare professional about every prescription medicine, over-the-counter product, and supplement you use. This allows the prescriber or pharmacist to assess potential interactions and determine whether this treatment is appropriate for you.

Why proper medical supervision matters

Angina often reflects an underlying cardiovascular condition that requires comprehensive management. Your treatment plan may include lifestyle changes, blood-pressure and cholesterol management, antiplatelet therapy, other antianginal medicines, exercise recommendations, or additional cardiac evaluation. Metagard CR 35mg Tablet should therefore be viewed as one component of an individualized treatment strategy rather than a standalone solution.

Do not stop prescribed heart medicines suddenly without medical advice. Keep scheduled appointments so your doctor can assess symptom control and determine whether your treatment remains appropriate.

Frequently Asked Questions

1. What is Metagard CR 35mg Tablet used for?
It contains trimetazidine 35 mg and is used as add-on treatment for symptomatic stable angina in adults when first-line treatments do not adequately control symptoms or are not tolerated.

2. Does Metagard CR 35mg Tablet cure angina?
No. It helps manage symptoms associated with stable angina but does not cure the underlying coronary artery disease. It also does not treat an acute heart attack or sudden angina attack.

3. Can I take it during an angina attack?
No. Trimetazidine is not an emergency medicine for an acute angina attack. Follow your doctor’s emergency plan for sudden chest pain and seek urgent medical attention when appropriate.

4. Can people with kidney disease take it?
Some patients with moderate kidney impairment may require a reduced dosing frequency. Severe renal impairment is a contraindication. Your prescriber should assess kidney function before determining the dose.

5. Can people with Parkinson’s disease use it?
Trimetazidine is contraindicated in Parkinson’s disease and related movement disorders in current product information. Discuss alternatives with your physician.